Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Tryptamine Therapeutics ( (AU:TYP) ) is now available.
Tryptamine Therapeutics Limited has announced a change in the director’s interest in securities, specifically involving Chris Ntoumenopoulos. The changes include the acquisition of 8,750,000 ordinary fully paid shares and 4,375,000 options at $0.04 expiring on March 31, 2027. This adjustment in director’s holdings is part of a capital raising effort, reflecting strategic financial maneuvers to bolster the company’s market position.
More about Tryptamine Therapeutics
YTD Price Performance: -15.79%
Average Trading Volume: 1,658,752
Technical Sentiment Signal: Buy
Current Market Cap: A$40.85M
See more data about TYP stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue